CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net income (loss)	$ 117,237	$ (110,938)	$ (34,625)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,392	5,401	216
Realized (gain) loss on marketable securities	293	(2,349)	(374)
Gain upon divestiture of Pediatric Priority Review Voucher	(140,004)	0
Gain upon divestiture of assets to Turing Pharmaceuticals	(914)	0
Deferred income tax	(15,573)	(2,460)	76
Settlement expense	0	5,746	0
Loss on extinguishment of debt	4,151	0	0
Impairment of intangible assets	4,710	0	0
Loss on disposal of fixed assets	112	0
Derivative financial instruments, warrants, issued, recorded in interest expense	1,050	0	0
Interest receivable from notes receivable	(1,267)	0	0
Non-Cash interest expense	2,461
Amortization of debt discount and deferred financing costs	1,340	1,084	0
Amortization of premiums on investments	398	0	0
2013 private placement settlement	0	272	0
Non-cash financing cost	0	4,708	0
Loss on impairment of cost method purchase	0	400	0
Share based compensation	25,900	15,900	5,444
Shares issued on behalf of related party	0	0	81
Registration payment obligation expense	0	0	360
Reversal of registration payment obligation liability	0	0	(360)
Bargain purchase gain	(49,063)	0	0
Change in estimated fair value of contingent consideration, net of payments	13,288	0	0
Change in estimated fair value of liability classified warrants	33,307	23,786	10,100
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	(4,504)	(7,959)	0
Inventory	(1,174)	(282)	0
Prepaid expenses and other current assets	(966)	237	(1,349)
Prepaid income taxes	(8,107)	0	0
Accounts payable and accrued expenses	3,379	20,604	2,842
Net cash used in operating activities	(554)	(45,850)	(17,589)
Cash Flows From Investing Activities:
Purchase of fixed assets	(22)	(663)	(117)
Purchase of intangible assets	(7,008)	(3,301)	(5,433)
Security deposits	0	(93)	(106)
Repayment of technology license liability	0	0	(1,300)
Proceeds from the sale/maturity of marketable securities	9,977	6,493	4,385
Purchase of marketable securities	(198,530)	(10,149)	(4,124)
Proceeds from securities sold, not yet purchased	0	7,500	4,194
Securities sold, not yet purchased	0	(7,500)	(2,865)
Increase in restricted cash	0	0	(40)
Cash received upon sale of assets, net	148,411	0	0
Cash paid for investment	0	(400)	0
Cash paid upon acquisition, net of cash acquired	(33,430)	(29,150)	0
Net cash used in investing activities	(80,602)	(37,263)	(5,406)
Cash Flows From Financing Activities:
Repayment of net amounts due to related parties	0	0	(13)
Payment of acquisition-related contingent consideration	(3,938)	(1,163)	0
Payment of other liability	(2,000)	(500)	0
Payment of guaranteed minimum royalty	(2,000)	0	0
Repayment of note payable - related party	0	0	(885)
Investors' deposits	0	0	(100)
Proceeds from credit agreement	0	42,366	0
Proceeds from Note Purchase Agreement	0	42,924	0
Proceeds from exercise of warrants	4,475	8,398	0
Proceeds from exercise of stock options	6,818	0	0
Repayment of Manchester note payable	0	(31,283)	0
Excess tax benefit related to stock compensation	2,425	0	0
Proceeds received from issuance of common stock	149,487	40,000	30,937
Financing costs from issuance of common stock	(9,500)	(3,165)	0
Repayment of credit facility	(45,000)	0	0
Purchase of treasury stock, at cost	0	(2,257)	(958)
Net cash provided by financing activities	100,767	95,320	28,981
Effect of exchange rate changes on cash	(10)	0	0
Net increase in cash and cash equivalents	19,601	12,207	5,986
Cash and cash equivalents, beginning of year	18,204	5,997	11
Cash and cash equivalents, end of year	37,805	18,204	5,997
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	5,838	4,080	28
Cash paid for income taxes	9,610	5	0
Non-cash Investing and financing activities:
Accrued royalty in excess of minimum payable to the sellers of Thiola	8,219	0	0
Present value of contingent consideration payable to sellers of Asklepion Pharmaceuticals LLC	42,010	0	0
Shares issued in connection with Cholbam acquisition	15,844	0	0
Reclassification of derivative liability to equity due to exercise of warrants	23,537	23,365	0
Present value of contingent consideration payable to sellers of Manchester Pharmaceuticals, LLC.	0	12,800	0
Present value of guaranteed minimum royalty payable to sellers of Thiola	0	11,850	0
Note payable entered into upon consummation of Manchester Pharmaceuticals, LLC.	0	31,283	0
Unrealized loss on securities sold, not yet purchased	0	0	(113)
Adjustment to existing shareholders	0	0	10
Purchase of Kyalin in exchange for future consideration	0	1,000	2,635
Affiliate receivable applied to security deposit	0	0	138
Share based payment made to investors for inducement to participate in financing	0	0	1,324
Offering expense liability	0	0	747
Increase in basis of indefinite lived intangible assets acquired from Kyalin due to accrual of deferred tax liability	$ 0	$ 0	$ 2,525